source
- Expert warns that newer obesity GLP-1 drugs could spark access battles in low-income nationsLower‑cost generic versions of semaglutide, sold as Wegovy for obesity, have begun appearing in several markets and are expected to reach more countries soon. At the same time, pharmaceutical compa…
- Biotech sector rebounds but gains are uneven, with Chinese firms and a large Sofinnova fund leading the surgeBiotech companies are experiencing a strong year overall, yet investor reactions to positive clinical data remain mixed. Chinese biotech firms are emerging as the top performers, outpacing many pe…